Skip to main content
SpringerLink
Log in

Does evidence from RCTs suggest: SGLT2 inhibitors could not reduce myocardial infarction and stroke?

  • Correspondence
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

A Correction to this article was published on 16 September 2022

This article has been updated

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability statement

This article does not have any relevant original data.

Change history

References

  1. Seo B, Su J, Song Y (2022) Exploring heterogeneities of cardiovascular efficacy and effectiveness of SGLT2 inhibitors in patients with type 2 diabetes: an umbrella review of evidence from randomized clinical trials versus real-world observational studies. Eur J Clin Pharmacol

  2. Kaze AD, Zhuo M, Kim SC, Patorno E, Paik JM (2022) Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovasc Diabetol 21(1):47

    Article  CAS  Google Scholar 

  3. Salah HM, Al’Aref SJ, Khan MS et al (2021) Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: a meta-analysis update. Am Heart J 233:86–91

    Article  CAS  Google Scholar 

  4. Zhao LM, Huang JN, Qiu M, Ding LL, Zhan ZL, Ning J (2021) Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases: a meta-analysis of cardiovascular outcome trials. Medicine (Baltimore) 100(39):e27362

    Article  CAS  Google Scholar 

  5. Teo YN, Ting A, Teo YH et al (2022) Effects of sodium/glucose cotransporter 2 (SGLT2) inhibitors and combined SGLT1/2 inhibitors on cardiovascular, metabolic, renal, and safety outcomes in patients with diabetes: a network meta-analysis of 111 randomized controlled trials. Am J Cardiovasc Drugs 22(3):299–323

    Article  CAS  Google Scholar 

  6. Avgerinos I, Karagiannis T, Kakotrichi P et al (2022) Sotagliflozin for patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 24(1):106–114

    Article  CAS  Google Scholar 

  7. Tsai WH, Chuang SM, Liu SC et al (2021) Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis. Sci Rep 11(1):15364

    Article  CAS  Google Scholar 

Download references

Funding

This work was supported by the Key Laboratory of Neuroimaging, Longhua District, Shenzhen (Shen Long Hua Ke Chuang Ke Ji Zi (2022) No. 7); and Shenzhen Fundamental Research Program (Natural Science Foundations), General Programe for Fundamental Research (Grant No. JCYJ20210324142404012).

Author information

Authors and Affiliations

  1. Department of Medical Imaging, Shenzhen Longhua District Central Hospital, Shenzhen, 518110, China

    Lixin Du, Zhigang Li, Peng Lan & Huayu Huang

  2. Department of Pathology, Shenzhen Longhua District Central Hospital, Shenzhen, 518110, China

    Wende Cheng

  3. Department of Radiology, Shenzhen Second People’s Hospital, Shenzhen, 518035, China

    Jun Xia

Authors
  1. Lixin Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhigang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peng Lan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Huayu Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wende Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jun Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Lixin Du and Jun Xia wrote the main manuscript text. All authors reviewed and approved the manuscript.

Corresponding author

Correspondence to Jun Xia.

Ethics declarations

Competing interests

The authors declare no competing interests.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original online version of this article was revised: First word of the article title should be Does not Dose.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Du, L., Li, Z., Lan, P. et al. Does evidence from RCTs suggest: SGLT2 inhibitors could not reduce myocardial infarction and stroke?. Eur J Clin Pharmacol 78, 1703–1704 (2022). https://doi.org/10.1007/s00228-022-03377-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-022-03377-0

Search

Navigation